Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Aduro Biotech Announces First Patient Dosed in Combination Clinical Trial of CRS-207 and Epacadostat to Treat Ovarian Cancer

Source Link:: http://phoenix.corporate-ir.net/phoenix.zhtml?c=242043&p=irol-newsArticle&ID=2150704

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

ADRO

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details the first patient has been dosed in SEASCAPE, the Phase 1/2 clinical study designed to evaluate the safety, tolerability and preliminary efficacy of CRS-207, Aduro’s lead listeria-based immunotherapy construct (LADD), in combination with epacadostat (INCB24360), Incyte Corporation’s (Nasdaq:INCY) selective IDO1 inhibitor, in patients with ovarian cancer.

http://phoenix.corpo...

Clinical Data SEASCAPE (Study of Epacadostat and CRS-207 in Adults with Platinum Resistant Ovarian Cancer), co-funded byIncyte and Aduro, is designed to establish a recommended dose based on safety and tumor biomarkers for CRS-207 and epacadostat in Phase 1 followed by expansion into Phase 2 which will evaluate the combination at the recommended (or identified) dose level compared to CRS-207 alone. Aduro plans to enroll up to 40 patients in Phase 1 and up to 86 patients in Phase 2 with platinum-resistant ovarian, fallopian or peritoneal cancers. For more information about the study, visit www.clinicaltrials.gov and search identifier NCT02575807.

http://phoenix.corpo...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Mar 24, 2016

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Crs-207, Epacadostat, Ovarian Cancer, Sting Pathway, Listeria-based Therapy, Ladd, Listeria, Immunotherapy, Ido1 Inhibitor, Epacadostat